We are harnessing the dynamic rules of amyloid assembly to design novel small-molecule medicines that block the production of toxic fleeting protein intermediates that are central to neurodegenerative disease pathways.

Our repeatable technology enables a pipeline of products for diseases with significant unmet needs. Our initial focus is on Alzheimer’s disease and Parkinson’s disease.